Oppenheimer Maintains Outperform on CME Gr, Raises Price Target to $258
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Owen Lau has maintained an 'Outperform' rating on CME Group (NASDAQ:CME) and raised the price target from $245 to $258.
October 24, 2024 | 2:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reaffirmed its 'Outperform' rating for CME Group and increased the price target to $258, indicating a positive outlook.
The increase in price target from $245 to $258 by Oppenheimer suggests a positive outlook for CME Group, likely boosting investor confidence and potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100